PTU - Polskie Towarzystwo Urologiczne
list of articles:

Urinary lithiasis (part II). Metabolic factors associated with urolithiasis
Article published in Urologia Polska 2005/58/3.


Bożena Eberdt-Gołąbek
Instytut Matki i Dziecka w Warszawie, Klinika Pediatrii
Dyrektor instytutu: prof. dr hab. Wojciech Woźniak
Kierownik kliniki: prof. dr hab. Andrzej Milanowski


urinary tract, urinary lithiasis, metabolic urolithiasis


Urinary lithiasis is not always limited to stone formation which can be treated surgically. Frequently it is associated with inborn abnormalities of metabolism of different etiology and this leads to slow progressive urinary lithiasis. For this reason the diagnostic search for precise etiological factors is decisive in implementing effective prophylactic treatment. Metabolic disturbances resulting in urinary lithiasis are the most common etiological group in the research studies of highly specialistic centres. In view of the frequently familial character of urinary lithiasis, establishing the precise nature of metabolic disturbances will help to identify other symptomless cases in the family. In the presentation, urinary lithiasis associated with the following metabolic disturbances are discussed. These are: idiopathic hypercalcuria, primary hyperparathyroidism, primary renal tubular acidosis, primary hyperoxaluria, xanthinuria, cystinuria.
The aim of the study.
The aim of the study is to discuss the metabolic aspects of urinary lithiasis.
Inborn abnormalities of metabolism are the most frequent cause of urolithiasis. Each patient with urinary lithiasis should undergo diagnostic procedures in order to establish the precise etiology. This is decisive in implementing effective prophylaxis.


  1. Floks RH: Calcium and phosphorus secretion in the urine of patients with renal or ureteral calculi. J Am Med Assoc 1939; 113; 1466-1471.
  2. Pak ChY, Kaplan R, Bone H et al: A simple test for the diagnosis of absorptive resorptive and reanl hypercalciurias. N Engl J Med 1975; 292; 497-501.
  3. Coe FL, Cantenbury JM, Firpo JJ et al: Evidence for secondary hyperparathyroidism in idiopathic hypercalciuria. J Clin Invest 1973; 52; 134-138.
  4. Brodus AE: Nephrogenous cyclic AMP as a parathyroid function test. Nephron 1979; 736; 136-141.
  5. Muldowney FP: Diagnostic approach to hypercalciuria. Kidney Int 1979; 16; 637-648.
  6. Garcia-Nieto V, Navarro JF: Bone mineral density in girls and their mothers with idiopathic hypercalciuria. Nephron Clin Pract 2003; 94; 89-93.
  7. Caudarella R, Vescini F: Osteoporosis and urolithiasis. Urol Int 2004; 72 Suppl 1; 17-19.
  8. Aladjem M, Barr J, Lahat E et al: Renal and absorptive hypercalciuria evidence for renal tubular calcium leak: A metabolic disturbance with varying and interchanging modes of expression. Pediatrics 1996; 97; 216-219.
  9. Aladjem M, Modan M et al: Idiopathic hypercalciuria: A familial generalized renal hyperexcretory state. Kidney Internat 1983; 24; 549-554.
  10. Kimira M, Kudo Y, Takachi R et al: Association between dietary intake and urinary excretion of sodium, potasium, phosphorus, magnesium and calcium. Nippon Eiseigaku Zashi 2004; 59; 23-26.
  11. Hsu SC, Levine MA: Primary hyperparathyroidism in children and adolescents: the Jahns Hopkins Children?s Center experience 1984-2001. J Bone Miner Res 2002; 17; 44-46.
  12. Kollars J, Zarroug AE, van Heerden J et al: Primary hyperparathyroidism in pediatric patients. Pediatrics 2005; 115; 974-980.
  13. Williams HE, Smith LH: Disorders of oxalate metabolism. Am J Med 1968; 45; 715-735.
  14. Chetyrkin SV, Kim D, Belmont JM et al: Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: a potential therapy for prymary hyperoxaluria. Kidney Int 2005; 67; 53-60.
  15. Hoppe D, Langman CB: United states survey on diagnosis treatment and autcome of primary hyperoxaluria. Pediatr Nephrol 2003; 18; 986-991.
  16. Gutman AB, Yu T: Uric acid nepholithiasis. Am J Med 1968; 45; 757-779.
  17. Henneman PH, Wallach S, Dempsey EF et al: The matabolic effect responsible for uric acid stone formation. J Clin Invest 1962; 41; 537-542.
  18. Moe OW, Abate N, Sakhaee K: Pathophysiology of uric acid nephrolithiasis. Endocrinol Metab Clin North Am 2002; 31; 895-914.
  19. Abate N, Chandalia M, Cabo-Chan AV Jr et al: The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int 2004; 65; 386-392.
  20. Rieselbach RE, Sorensen LB, Shelp JD et al: Diminished renal urate secretion per nephron as a basis primary gout. Ann Intern Med 1970; 73; 359-366.
  21. Kirk JE, Praetorius E: Hypouricemia with evidence for tubular elimination of uric acid. J Lab Clin Med 1950; 35; 865-869.
  22. Seegmiiler JE: Xanthine stone formation. Am J Med 1968; 45; 780-789.
  23. Dent CE, Senior B, Walsh JM et al: The pathogenesis of cystynuria. Studies of the metabolism of sulphur containing aminoacids. J Clin Invest 1954; 33; 1216-1221.
  24. Crawhall JC, Purkiss P: The excretion of aminoacids by cystynuric patients and their relatives. Ann Hum Genet 1968; 45; 736-740.
  25. Thier O, Segal S: Cystynuria w: The metabolic basis of inherited disease. Stanbury J. Wangaarden J. (red.), Grow Hill Com 1978; 1505-1516.
  26. Rose DB: Cystine stones. UpToDate 2002; 10; 1.
  27. Rose DB: Cystine stones. UpToDate 2005; 13; 2.


Bożena Eberdt-Gołąbek
Klinika Pediatrii
ul. Kasprzaka 17a
01-211 Warszawa
tel. /fax (022) 32 77 043